I asked about this when I was evaluated and the center I was at said they were doing studies with it and that I could opt to try it if I wanted on a "compassionate care" basis....I believe that is the term they used. I did not end up being listed; but, I would have wanted to try it because I too have read many things about it. I say push for guys<img src="i/expressions/face-icon-small-smile.gif" border="0">
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
Inhaled Cyclosporine / Pulminiq
- Thread starter TwistedTanya
- Start date
I asked about this when I was evaluated and the center I was at said they were doing studies with it and that I could opt to try it if I wanted on a "compassionate care" basis....I believe that is the term they used. I did not end up being listed; but, I would have wanted to try it because I too have read many things about it. I say push for guys<img src="i/expressions/face-icon-small-smile.gif" border="0">
I asked about this when I was evaluated and the center I was at said they were doing studies with it and that I could opt to try it if I wanted on a "compassionate care" basis....I believe that is the term they used. I did not end up being listed; but, I would have wanted to try it because I too have read many things about it. I say push for guys<img src="i/expressions/face-icon-small-smile.gif" border="0">
I asked about this when I was evaluated and the center I was at said they were doing studies with it and that I could opt to try it if I wanted on a "compassionate care" basis....I believe that is the term they used. I did not end up being listed; but, I would have wanted to try it because I too have read many things about it. I say push for guys<img src="i/expressions/face-icon-small-smile.gif" border="0">
I asked about this when I was evaluated and the center I was at said they were doing studies with it and that I could opt to try it if I wanted on a "compassionate care" basis....I believe that is the term they used. I did not end up being listed; but, I would have wanted to try it because I too have read many things about it. I say push for guys<img src="i/expressions/face-icon-small-smile.gif" border="0">
Here is info on Inhaled cyclosporine! Please spread the word!
Are you waiting for a lung transplant or recently had one?
If so, read below!
Each year, lung transplantation is a life saving procedure for people with serious lung diseases. However, lung transplant recipients are at high risk for a life threatening complication called chronic rejection. Chronic rejection is an immune response that leads to worsening lung function and organ failure. There are currently no therapies approved to treat chronic rejection. Developing a better understanding of chronic rejection and finding ways to prevent and treat rejection is one of the most important areas for research in the field of lung transplantation.
The good news is that many of North America's leading lung transplant centers are currently recruiting patients for a clinical trial to evaluate the effects of an investigational drug called cyclosporine inhalation solution (CIS). The goal of the study, called CYCLIST, is to determine if CIS can safely reduce the occurrence of chronic rejection and extend life in lung transplant recipients.
Cyclosporine inhalation solution (CIS) is an inhaled formulation of cyclosporine, an oral medication that has been available for over twenty years to prevent rejection in transplant recipients. Inhaling cyclosporine provides a higher concentration of the drug directly into the lungs. CIS was originally developed and studied at the University of Pittsburgh beginning in 1988. Scientists have conducted nine preliminary studies in lung transplant recipients including a study published as the lead article in the New England Journal of Medicine .
Participants in the CYCLIST study will be making an important contribution to lung transplant medical research and will be eligible to receive the drug at no cost for life as long as the drug is still under investigation or is FDA approved. You may be eligible for CYCLIST if you are an adult on the waiting list to receive your first lung transplant or received your first transplant within the past two months at a participating center. More information about the study is available at www.cycliststudy.com or through a participating transplant center.
California UCSF
Stanford
UCLA New York Columbia
Ohio Cleveland Clinic
Colorado U. of Colorado Pennsylvania U. of Pennsylvania
U. of Pittsburgh
Florida Tampa General
U. of Fla Gainesville Texas Baylor, Houston
Illinois Loyola
U. of Chicago Virginia Inova Fairfax
Maryland U. of Maryland Ontario, Canada U. of Toronto
Minnesota U. of Minnesota
If you are a patient advocacy group or member of the media looking for more information, please contact the study's sponsor APT Pharmaceuticals at cyclist@aptbio.com
Are you waiting for a lung transplant or recently had one?
If so, read below!
Each year, lung transplantation is a life saving procedure for people with serious lung diseases. However, lung transplant recipients are at high risk for a life threatening complication called chronic rejection. Chronic rejection is an immune response that leads to worsening lung function and organ failure. There are currently no therapies approved to treat chronic rejection. Developing a better understanding of chronic rejection and finding ways to prevent and treat rejection is one of the most important areas for research in the field of lung transplantation.
The good news is that many of North America's leading lung transplant centers are currently recruiting patients for a clinical trial to evaluate the effects of an investigational drug called cyclosporine inhalation solution (CIS). The goal of the study, called CYCLIST, is to determine if CIS can safely reduce the occurrence of chronic rejection and extend life in lung transplant recipients.
Cyclosporine inhalation solution (CIS) is an inhaled formulation of cyclosporine, an oral medication that has been available for over twenty years to prevent rejection in transplant recipients. Inhaling cyclosporine provides a higher concentration of the drug directly into the lungs. CIS was originally developed and studied at the University of Pittsburgh beginning in 1988. Scientists have conducted nine preliminary studies in lung transplant recipients including a study published as the lead article in the New England Journal of Medicine .
Participants in the CYCLIST study will be making an important contribution to lung transplant medical research and will be eligible to receive the drug at no cost for life as long as the drug is still under investigation or is FDA approved. You may be eligible for CYCLIST if you are an adult on the waiting list to receive your first lung transplant or received your first transplant within the past two months at a participating center. More information about the study is available at www.cycliststudy.com or through a participating transplant center.
California UCSF
Stanford
UCLA New York Columbia
Ohio Cleveland Clinic
Colorado U. of Colorado Pennsylvania U. of Pennsylvania
U. of Pittsburgh
Florida Tampa General
U. of Fla Gainesville Texas Baylor, Houston
Illinois Loyola
U. of Chicago Virginia Inova Fairfax
Maryland U. of Maryland Ontario, Canada U. of Toronto
Minnesota U. of Minnesota
If you are a patient advocacy group or member of the media looking for more information, please contact the study's sponsor APT Pharmaceuticals at cyclist@aptbio.com
Here is info on Inhaled cyclosporine! Please spread the word!
Are you waiting for a lung transplant or recently had one?
If so, read below!
Each year, lung transplantation is a life saving procedure for people with serious lung diseases. However, lung transplant recipients are at high risk for a life threatening complication called chronic rejection. Chronic rejection is an immune response that leads to worsening lung function and organ failure. There are currently no therapies approved to treat chronic rejection. Developing a better understanding of chronic rejection and finding ways to prevent and treat rejection is one of the most important areas for research in the field of lung transplantation.
The good news is that many of North America's leading lung transplant centers are currently recruiting patients for a clinical trial to evaluate the effects of an investigational drug called cyclosporine inhalation solution (CIS). The goal of the study, called CYCLIST, is to determine if CIS can safely reduce the occurrence of chronic rejection and extend life in lung transplant recipients.
Cyclosporine inhalation solution (CIS) is an inhaled formulation of cyclosporine, an oral medication that has been available for over twenty years to prevent rejection in transplant recipients. Inhaling cyclosporine provides a higher concentration of the drug directly into the lungs. CIS was originally developed and studied at the University of Pittsburgh beginning in 1988. Scientists have conducted nine preliminary studies in lung transplant recipients including a study published as the lead article in the New England Journal of Medicine .
Participants in the CYCLIST study will be making an important contribution to lung transplant medical research and will be eligible to receive the drug at no cost for life as long as the drug is still under investigation or is FDA approved. You may be eligible for CYCLIST if you are an adult on the waiting list to receive your first lung transplant or received your first transplant within the past two months at a participating center. More information about the study is available at www.cycliststudy.com or through a participating transplant center.
California UCSF
Stanford
UCLA New York Columbia
Ohio Cleveland Clinic
Colorado U. of Colorado Pennsylvania U. of Pennsylvania
U. of Pittsburgh
Florida Tampa General
U. of Fla Gainesville Texas Baylor, Houston
Illinois Loyola
U. of Chicago Virginia Inova Fairfax
Maryland U. of Maryland Ontario, Canada U. of Toronto
Minnesota U. of Minnesota
If you are a patient advocacy group or member of the media looking for more information, please contact the study's sponsor APT Pharmaceuticals at cyclist@aptbio.com
Are you waiting for a lung transplant or recently had one?
If so, read below!
Each year, lung transplantation is a life saving procedure for people with serious lung diseases. However, lung transplant recipients are at high risk for a life threatening complication called chronic rejection. Chronic rejection is an immune response that leads to worsening lung function and organ failure. There are currently no therapies approved to treat chronic rejection. Developing a better understanding of chronic rejection and finding ways to prevent and treat rejection is one of the most important areas for research in the field of lung transplantation.
The good news is that many of North America's leading lung transplant centers are currently recruiting patients for a clinical trial to evaluate the effects of an investigational drug called cyclosporine inhalation solution (CIS). The goal of the study, called CYCLIST, is to determine if CIS can safely reduce the occurrence of chronic rejection and extend life in lung transplant recipients.
Cyclosporine inhalation solution (CIS) is an inhaled formulation of cyclosporine, an oral medication that has been available for over twenty years to prevent rejection in transplant recipients. Inhaling cyclosporine provides a higher concentration of the drug directly into the lungs. CIS was originally developed and studied at the University of Pittsburgh beginning in 1988. Scientists have conducted nine preliminary studies in lung transplant recipients including a study published as the lead article in the New England Journal of Medicine .
Participants in the CYCLIST study will be making an important contribution to lung transplant medical research and will be eligible to receive the drug at no cost for life as long as the drug is still under investigation or is FDA approved. You may be eligible for CYCLIST if you are an adult on the waiting list to receive your first lung transplant or received your first transplant within the past two months at a participating center. More information about the study is available at www.cycliststudy.com or through a participating transplant center.
California UCSF
Stanford
UCLA New York Columbia
Ohio Cleveland Clinic
Colorado U. of Colorado Pennsylvania U. of Pennsylvania
U. of Pittsburgh
Florida Tampa General
U. of Fla Gainesville Texas Baylor, Houston
Illinois Loyola
U. of Chicago Virginia Inova Fairfax
Maryland U. of Maryland Ontario, Canada U. of Toronto
Minnesota U. of Minnesota
If you are a patient advocacy group or member of the media looking for more information, please contact the study's sponsor APT Pharmaceuticals at cyclist@aptbio.com
Here is info on Inhaled cyclosporine! Please spread the word!
Are you waiting for a lung transplant or recently had one?
If so, read below!
Each year, lung transplantation is a life saving procedure for people with serious lung diseases. However, lung transplant recipients are at high risk for a life threatening complication called chronic rejection. Chronic rejection is an immune response that leads to worsening lung function and organ failure. There are currently no therapies approved to treat chronic rejection. Developing a better understanding of chronic rejection and finding ways to prevent and treat rejection is one of the most important areas for research in the field of lung transplantation.
The good news is that many of North America's leading lung transplant centers are currently recruiting patients for a clinical trial to evaluate the effects of an investigational drug called cyclosporine inhalation solution (CIS). The goal of the study, called CYCLIST, is to determine if CIS can safely reduce the occurrence of chronic rejection and extend life in lung transplant recipients.
Cyclosporine inhalation solution (CIS) is an inhaled formulation of cyclosporine, an oral medication that has been available for over twenty years to prevent rejection in transplant recipients. Inhaling cyclosporine provides a higher concentration of the drug directly into the lungs. CIS was originally developed and studied at the University of Pittsburgh beginning in 1988. Scientists have conducted nine preliminary studies in lung transplant recipients including a study published as the lead article in the New England Journal of Medicine .
Participants in the CYCLIST study will be making an important contribution to lung transplant medical research and will be eligible to receive the drug at no cost for life as long as the drug is still under investigation or is FDA approved. You may be eligible for CYCLIST if you are an adult on the waiting list to receive your first lung transplant or received your first transplant within the past two months at a participating center. More information about the study is available at www.cycliststudy.com or through a participating transplant center.
California UCSF
Stanford
UCLA New York Columbia
Ohio Cleveland Clinic
Colorado U. of Colorado Pennsylvania U. of Pennsylvania
U. of Pittsburgh
Florida Tampa General
U. of Fla Gainesville Texas Baylor, Houston
Illinois Loyola
U. of Chicago Virginia Inova Fairfax
Maryland U. of Maryland Ontario, Canada U. of Toronto
Minnesota U. of Minnesota
If you are a patient advocacy group or member of the media looking for more information, please contact the study's sponsor APT Pharmaceuticals at cyclist@aptbio.com
Are you waiting for a lung transplant or recently had one?
If so, read below!
Each year, lung transplantation is a life saving procedure for people with serious lung diseases. However, lung transplant recipients are at high risk for a life threatening complication called chronic rejection. Chronic rejection is an immune response that leads to worsening lung function and organ failure. There are currently no therapies approved to treat chronic rejection. Developing a better understanding of chronic rejection and finding ways to prevent and treat rejection is one of the most important areas for research in the field of lung transplantation.
The good news is that many of North America's leading lung transplant centers are currently recruiting patients for a clinical trial to evaluate the effects of an investigational drug called cyclosporine inhalation solution (CIS). The goal of the study, called CYCLIST, is to determine if CIS can safely reduce the occurrence of chronic rejection and extend life in lung transplant recipients.
Cyclosporine inhalation solution (CIS) is an inhaled formulation of cyclosporine, an oral medication that has been available for over twenty years to prevent rejection in transplant recipients. Inhaling cyclosporine provides a higher concentration of the drug directly into the lungs. CIS was originally developed and studied at the University of Pittsburgh beginning in 1988. Scientists have conducted nine preliminary studies in lung transplant recipients including a study published as the lead article in the New England Journal of Medicine .
Participants in the CYCLIST study will be making an important contribution to lung transplant medical research and will be eligible to receive the drug at no cost for life as long as the drug is still under investigation or is FDA approved. You may be eligible for CYCLIST if you are an adult on the waiting list to receive your first lung transplant or received your first transplant within the past two months at a participating center. More information about the study is available at www.cycliststudy.com or through a participating transplant center.
California UCSF
Stanford
UCLA New York Columbia
Ohio Cleveland Clinic
Colorado U. of Colorado Pennsylvania U. of Pennsylvania
U. of Pittsburgh
Florida Tampa General
U. of Fla Gainesville Texas Baylor, Houston
Illinois Loyola
U. of Chicago Virginia Inova Fairfax
Maryland U. of Maryland Ontario, Canada U. of Toronto
Minnesota U. of Minnesota
If you are a patient advocacy group or member of the media looking for more information, please contact the study's sponsor APT Pharmaceuticals at cyclist@aptbio.com
Here is info on Inhaled cyclosporine! Please spread the word!
Are you waiting for a lung transplant or recently had one?
If so, read below!
Each year, lung transplantation is a life saving procedure for people with serious lung diseases. However, lung transplant recipients are at high risk for a life threatening complication called chronic rejection. Chronic rejection is an immune response that leads to worsening lung function and organ failure. There are currently no therapies approved to treat chronic rejection. Developing a better understanding of chronic rejection and finding ways to prevent and treat rejection is one of the most important areas for research in the field of lung transplantation.
The good news is that many of North America's leading lung transplant centers are currently recruiting patients for a clinical trial to evaluate the effects of an investigational drug called cyclosporine inhalation solution (CIS). The goal of the study, called CYCLIST, is to determine if CIS can safely reduce the occurrence of chronic rejection and extend life in lung transplant recipients.
Cyclosporine inhalation solution (CIS) is an inhaled formulation of cyclosporine, an oral medication that has been available for over twenty years to prevent rejection in transplant recipients. Inhaling cyclosporine provides a higher concentration of the drug directly into the lungs. CIS was originally developed and studied at the University of Pittsburgh beginning in 1988. Scientists have conducted nine preliminary studies in lung transplant recipients including a study published as the lead article in the New England Journal of Medicine .
Participants in the CYCLIST study will be making an important contribution to lung transplant medical research and will be eligible to receive the drug at no cost for life as long as the drug is still under investigation or is FDA approved. You may be eligible for CYCLIST if you are an adult on the waiting list to receive your first lung transplant or received your first transplant within the past two months at a participating center. More information about the study is available at www.cycliststudy.com or through a participating transplant center.
California UCSF
Stanford
UCLA New York Columbia
Ohio Cleveland Clinic
Colorado U. of Colorado Pennsylvania U. of Pennsylvania
U. of Pittsburgh
Florida Tampa General
U. of Fla Gainesville Texas Baylor, Houston
Illinois Loyola
U. of Chicago Virginia Inova Fairfax
Maryland U. of Maryland Ontario, Canada U. of Toronto
Minnesota U. of Minnesota
If you are a patient advocacy group or member of the media looking for more information, please contact the study's sponsor APT Pharmaceuticals at cyclist@aptbio.com
Are you waiting for a lung transplant or recently had one?
If so, read below!
Each year, lung transplantation is a life saving procedure for people with serious lung diseases. However, lung transplant recipients are at high risk for a life threatening complication called chronic rejection. Chronic rejection is an immune response that leads to worsening lung function and organ failure. There are currently no therapies approved to treat chronic rejection. Developing a better understanding of chronic rejection and finding ways to prevent and treat rejection is one of the most important areas for research in the field of lung transplantation.
The good news is that many of North America's leading lung transplant centers are currently recruiting patients for a clinical trial to evaluate the effects of an investigational drug called cyclosporine inhalation solution (CIS). The goal of the study, called CYCLIST, is to determine if CIS can safely reduce the occurrence of chronic rejection and extend life in lung transplant recipients.
Cyclosporine inhalation solution (CIS) is an inhaled formulation of cyclosporine, an oral medication that has been available for over twenty years to prevent rejection in transplant recipients. Inhaling cyclosporine provides a higher concentration of the drug directly into the lungs. CIS was originally developed and studied at the University of Pittsburgh beginning in 1988. Scientists have conducted nine preliminary studies in lung transplant recipients including a study published as the lead article in the New England Journal of Medicine .
Participants in the CYCLIST study will be making an important contribution to lung transplant medical research and will be eligible to receive the drug at no cost for life as long as the drug is still under investigation or is FDA approved. You may be eligible for CYCLIST if you are an adult on the waiting list to receive your first lung transplant or received your first transplant within the past two months at a participating center. More information about the study is available at www.cycliststudy.com or through a participating transplant center.
California UCSF
Stanford
UCLA New York Columbia
Ohio Cleveland Clinic
Colorado U. of Colorado Pennsylvania U. of Pennsylvania
U. of Pittsburgh
Florida Tampa General
U. of Fla Gainesville Texas Baylor, Houston
Illinois Loyola
U. of Chicago Virginia Inova Fairfax
Maryland U. of Maryland Ontario, Canada U. of Toronto
Minnesota U. of Minnesota
If you are a patient advocacy group or member of the media looking for more information, please contact the study's sponsor APT Pharmaceuticals at cyclist@aptbio.com
Here is info on Inhaled cyclosporine! Please spread the word!
<br />
<br />Are you waiting for a lung transplant or recently had one?
<br />If so, read below!
<br />
<br />Each year, lung transplantation is a life saving procedure for people with serious lung diseases. However, lung transplant recipients are at high risk for a life threatening complication called chronic rejection. Chronic rejection is an immune response that leads to worsening lung function and organ failure. There are currently no therapies approved to treat chronic rejection. Developing a better understanding of chronic rejection and finding ways to prevent and treat rejection is one of the most important areas for research in the field of lung transplantation.
<br />
<br />The good news is that many of North America's leading lung transplant centers are currently recruiting patients for a clinical trial to evaluate the effects of an investigational drug called cyclosporine inhalation solution (CIS). The goal of the study, called CYCLIST, is to determine if CIS can safely reduce the occurrence of chronic rejection and extend life in lung transplant recipients.
<br />
<br />Cyclosporine inhalation solution (CIS) is an inhaled formulation of cyclosporine, an oral medication that has been available for over twenty years to prevent rejection in transplant recipients. Inhaling cyclosporine provides a higher concentration of the drug directly into the lungs. CIS was originally developed and studied at the University of Pittsburgh beginning in 1988. Scientists have conducted nine preliminary studies in lung transplant recipients including a study published as the lead article in the New England Journal of Medicine .
<br />
<br />Participants in the CYCLIST study will be making an important contribution to lung transplant medical research and will be eligible to receive the drug at no cost for life as long as the drug is still under investigation or is FDA approved. You may be eligible for CYCLIST if you are an adult on the waiting list to receive your first lung transplant or received your first transplant within the past two months at a participating center. More information about the study is available at www.cycliststudy.com or through a participating transplant center.
<br />
<br />California UCSF
<br />Stanford
<br />UCLA New York Columbia
<br />Ohio Cleveland Clinic
<br />Colorado U. of Colorado Pennsylvania U. of Pennsylvania
<br />U. of Pittsburgh
<br />Florida Tampa General
<br />U. of Fla Gainesville Texas Baylor, Houston
<br />Illinois Loyola
<br />U. of Chicago Virginia Inova Fairfax
<br />Maryland U. of Maryland Ontario, Canada U. of Toronto
<br />Minnesota U. of Minnesota
<br />
<br />If you are a patient advocacy group or member of the media looking for more information, please contact the study's sponsor APT Pharmaceuticals at cyclist@aptbio.com
<br />
<br />Are you waiting for a lung transplant or recently had one?
<br />If so, read below!
<br />
<br />Each year, lung transplantation is a life saving procedure for people with serious lung diseases. However, lung transplant recipients are at high risk for a life threatening complication called chronic rejection. Chronic rejection is an immune response that leads to worsening lung function and organ failure. There are currently no therapies approved to treat chronic rejection. Developing a better understanding of chronic rejection and finding ways to prevent and treat rejection is one of the most important areas for research in the field of lung transplantation.
<br />
<br />The good news is that many of North America's leading lung transplant centers are currently recruiting patients for a clinical trial to evaluate the effects of an investigational drug called cyclosporine inhalation solution (CIS). The goal of the study, called CYCLIST, is to determine if CIS can safely reduce the occurrence of chronic rejection and extend life in lung transplant recipients.
<br />
<br />Cyclosporine inhalation solution (CIS) is an inhaled formulation of cyclosporine, an oral medication that has been available for over twenty years to prevent rejection in transplant recipients. Inhaling cyclosporine provides a higher concentration of the drug directly into the lungs. CIS was originally developed and studied at the University of Pittsburgh beginning in 1988. Scientists have conducted nine preliminary studies in lung transplant recipients including a study published as the lead article in the New England Journal of Medicine .
<br />
<br />Participants in the CYCLIST study will be making an important contribution to lung transplant medical research and will be eligible to receive the drug at no cost for life as long as the drug is still under investigation or is FDA approved. You may be eligible for CYCLIST if you are an adult on the waiting list to receive your first lung transplant or received your first transplant within the past two months at a participating center. More information about the study is available at www.cycliststudy.com or through a participating transplant center.
<br />
<br />California UCSF
<br />Stanford
<br />UCLA New York Columbia
<br />Ohio Cleveland Clinic
<br />Colorado U. of Colorado Pennsylvania U. of Pennsylvania
<br />U. of Pittsburgh
<br />Florida Tampa General
<br />U. of Fla Gainesville Texas Baylor, Houston
<br />Illinois Loyola
<br />U. of Chicago Virginia Inova Fairfax
<br />Maryland U. of Maryland Ontario, Canada U. of Toronto
<br />Minnesota U. of Minnesota
<br />
<br />If you are a patient advocacy group or member of the media looking for more information, please contact the study's sponsor APT Pharmaceuticals at cyclist@aptbio.com
dirtbike32883333
New member
I have been on this drug for a few weeks at a time. It really aggravates my throat and produces more mucus. By the time i recovered from the side effects it was time for another treament. Typically given 3 times a week, inhaled for about an hour and my doctor only does it at a pulmonary lab. So if you planing on traveling its not very ideal. I have herd good results but it does come with a cost. They normally give you lovacain to numb your throat so it doesnt get so irritated.
dirtbike32883333
New member
I have been on this drug for a few weeks at a time. It really aggravates my throat and produces more mucus. By the time i recovered from the side effects it was time for another treament. Typically given 3 times a week, inhaled for about an hour and my doctor only does it at a pulmonary lab. So if you planing on traveling its not very ideal. I have herd good results but it does come with a cost. They normally give you lovacain to numb your throat so it doesnt get so irritated.
dirtbike32883333
New member
I have been on this drug for a few weeks at a time. It really aggravates my throat and produces more mucus. By the time i recovered from the side effects it was time for another treament. Typically given 3 times a week, inhaled for about an hour and my doctor only does it at a pulmonary lab. So if you planing on traveling its not very ideal. I have herd good results but it does come with a cost. They normally give you lovacain to numb your throat so it doesnt get so irritated.
dirtbike32883333
New member
I have been on this drug for a few weeks at a time. It really aggravates my throat and produces more mucus. By the time i recovered from the side effects it was time for another treament. Typically given 3 times a week, inhaled for about an hour and my doctor only does it at a pulmonary lab. So if you planing on traveling its not very ideal. I have herd good results but it does come with a cost. They normally give you lovacain to numb your throat so it doesnt get so irritated.
dirtbike32883333
New member
I have been on this drug for a few weeks at a time. It really aggravates my throat and produces more mucus. By the time i recovered from the side effects it was time for another treament. Typically given 3 times a week, inhaled for about an hour and my doctor only does it at a pulmonary lab. So if you planing on traveling its not very ideal. I have herd good results but it does come with a cost. They normally give you lovacain to numb your throat so it doesnt get so irritated.